검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Checkpoint inhibitor therapy (Checkpoint inhibitor therapy) Boundless Bio, Inc.·Autoimmune Diseases ORR 59% |
|---|---|
Overview Program | Checkpoint inhibitor therapy |
Overview Company | Boundless Bio, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Autoimmune Diseases |
Overview Indication | Autoimmune Diseases; Advanced Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study.. For recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) that has progressed after platinum-based chemotherapy or immunotherapy, treatment options are limited. This real-world stu… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Checkpoint inhibitor therapy (Checkpoint inhibitor therapy) Boundless Bio, Inc.·Autoimmune Diseases ORR 59% |
|---|---|
Overview Program | Checkpoint inhibitor therapy |
Overview Company | Boundless Bio, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Autoimmune Diseases |
Overview Indication | Autoimmune Diseases; Advanced Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathway |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study.. For recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) that has progressed after platinum-based chemotherapy or immunotherapy, treatment options are limited. This real-world stu… |
Clinical Primary efficacy | ORR 59% |
Clinical ORR | 59% |
Clinical Result source | ClinicalTrials.gov NCT03729245 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교